Nurix Therapeutics Inc
For the period ended Feb 29, 2024. Filed Apr 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Feb 29, 2024 · Filed Apr 10, 2024
NRIX$15.88-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Accumulated deficit · Totalstockholders’equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of November 30, 2022 | 47,172,299 | $47 | $709,220 | $(4,319) | $(401,252) | $303,696 |
| Exercise of stock options | 8,768 | — | 28 | — | — | 28 |
| Vesting of restricted stock units | 98,571 | — | — | — | — | — |
| Vesting of early exercised stock options | — | — | 31 | — | — | 31 |
| Issuance under employee stock purchase plan | 165,215 | — | 1,453 | — | — | 1,453 |
| Stock-based compensation | — | — | 8,505 | — | — | 8,505 |
| Unrealized gain on available-for-sale marketable securities | — | — | — | 1,072 | — | 1,072 |
| Net loss | — | — | — | — | (40,733) | (40,733) |
| Balance as of February 28, 2023 | 47,444,853 | $47 | $719,237 | $(3,247) | $(441,985) | $274,052 |
| Common stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Accumulateddeficit · Totalstockholders’equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of November 30, 2023 | 48,718,552 | $49 | $746,299 | $(655) | $(545,200) | $200,493 |
| Exercise of stock options | 75,362 | — | 355 | — | — | 355 |
| Vesting of restricted stock units | 171,030 | — | — | — | — | — |
| Vesting of early exercised stock options | — | — | 21 | — | — | 21 |
| Repurchase of unvested early exercised stock | (1,548) | — | — | — | — | — |
| Issuance under employee stock purchase plan | 173,558 | — | 1,269 | — | — | 1,269 |
| Stock-based compensation | — | — | 7,823 | — | — | 7,823 |
| Unrealized gain on available-for-sale marketable securities | — | — | — | 305 | — | 305 |
| Net loss | — | — | — | — | (41,518) | (41,518) |
| Balance as of February 29, 2024 | 49,136,954 | $49 | $755,767 | $(350) | $(586,718) | $168,748 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.